RxDoctor Payments Data

Jonathan Martin, MD

Neurology · Attleboro, MANPI 1790793529

Payments from drug & device makers

$3,291in general payments, 2019–2025

Across 143 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$639
  • Genentech USA, Inc.$278
  • SK Life Science, Inc.$205
  • Johnson & Johnson$174
  • Sanofi$99
  • plus $760 from 18 others

What the payments were for

  • Food & beverage$3,18597%
  • Education$1063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,291 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$43,508
Medicare patients
177
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality SyringeGalcanezumab-Gnlm41$42,137
Glatiramer Acetate31$42,105
UbrelvyUbrogepant29$33,430
XcopriCenobamate23$26,169
BotoxOnabotulinumtoxina20$24,673
QuliptaAtogepant17$18,367
Emgality PenGalcanezumab-Gnlm16$13,128
MyrbetriqMirabegron21$9,908
Pramipexole ErPramipexole Di-Hcl12$5,462
Dalfampridine ErDalfampridine11$4,461
Rasagiline Mesylate14$4,159
TegretolCarbamazepine13$3,745
Carbamazepine ErCarbamazepine23$2,504
Baclofen65$2,474
Sumatriptan Succinate34$2,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$1,136$76,46966 claims
SK Life Science, Inc.Xcopri$205$26,16923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 761 neurology providers in Massachusetts.

Other neurology in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →